Mograflox®( Moxifloxacin Hcl ophthalmic solution)<br /> is a sterile ophthalmic solution. <br /><ul><li>It is an 8-methoxy fluoroquinolone anti-infective for topical ophthalmic use.</li></ul>Structure and Empirical Formula:<br />
Moxifloxacin is a synthetic fluoroquinolone antibacterial agent active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens.<br />Mechanism of action<br />
<ul><li>DNA gyraseis an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA.
Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.</li></li></ul><li>Kinetics <br />
<ul><li>The mean steady-state Cmax and AUC were 2.7 ng/mL and 41.9 ngAhr/mL, respectively.
The plasma half-life of moxifloxacin was estimated to be 13 hours.</li></li></ul><li>Mograflox®ophthalmic solution is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis & Keratitis caused by susceptible strains of the following organisms:<br />Aerobic, Gram-Positive<br />Staphylococcus aureus<br />Staphylococcus epidermidis<br />Staphylococcus haemolyticus<br />Staphylococcus hominis<br />Streptococcus pneumoniae<br />Streptococcus viridansgroup<br />Aerobic, Gram-Negative<br />Acinetobacterspecies<br />Haemophilusinfluenzae<br />
Mograflox®is also effective against:<br />MRSA and Pseudomonas aeruginosa<br />Moxifloxacin has a good activity against Pseudomonas aeruginosa. assisted by its excellent penetration power into the cornea which is much higher than Ciprofloxacin (used as a traditional therapy in Pseudomonas corneal ulcers before).<br />
<ul><li>Mograflox®ophthalmic solution is not for injection into the eye.
Mograflox®Solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.</li></li></ul><li>Precautions<br />
<ul><li>General: As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. </li></ul>If super infection occurs, discontinue use and institute alternative therapy.<br /><ul><li>Patients should be advised not to wear contact lenses if they</li></ul>have signs and symptoms of bacterial conjunctivitis.<br />X<br />
<ul><li>Safety and effectiveness in infants below the age of one year have not been established.</li></li></ul><li>Drug interaction<br />
Drug-drug interaction studies have not been conducted with Mograflox®solution.<br />
<ul><li>The most frequently reported treatment-related adverse drug reactions were transient eye irritation</li></ul>(3.9%) (burning and/or stinging) and eye pruritus (1.1%).<br /><ul><li>Treatment-related adverse drug reactions that occurred at an incidence of 0.1% to less than 1.0% included the following:</li></ul>Eye disorders: ocular hyperaemia, keratoconjunctivitissicca, abnormal sensation in eye, ocular<br />discomfort, corneal epithelium defect,<br />conjunctivitis, conjunctival haemorrhage, visual<br />acuity reduced, eyelid oedema, eye pain.<br />
<ul><li>General disorders and administration site conditions: </li></ul>sensation of foreign body.<br /><ul><li>Investigations: corneal staining, alanine aminotransferase increased.</li></li></ul><li>Dosage & administration<br />
The recommended dosage regimen for patients<br />one year of age and older is one drop in the affected<br />eye(s) 3 times a day for 7 days.<br />
BenzalkoniumChloride..is it valuable? <br />1- BAK is active against bacteria, some viruses, fungi and protozoa.<br />2- Enhances medication's absorption rate.<br />3- In some cases increases the speed of microbial killing.<br />4- Prevents contamination of the content of the bottle. <br />
Biocidal action of Benzalkoniumchloride<br />1- BAK causes dissociation of cellular membrane lipid bilayers, which compromises cellular permeability controls and induces leakage of cellular contents.<br />2- BAK Deactivates Enzymes, which finely control a wide range of respiratory and metabolic cellular activities.<br />
Benzalkonium chloride tolerability<br />In the patient with mild to moderate dry eye, BAK preserved solutions are usually well tolerated when used 4-6 times a day or less. <br />